The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1066
November 19, 1999
View Complete Issue         Table of Contents 2019 
Quinupristin/Dalfopristin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Quinupristin/Dalfopristin
November 19, 1999 (Issue: 1066)
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection....
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Quinupristin/Dalfopristin
Article code: 1066a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.